Versaggi seals deal for Xenogen and Uros work

SAN FRANCISCO: Versaggi Biocommunications has added two new accounts to its medical/biotech roster and is nearing an agreement with a third, president Charles Versaggi told PRWeek last week.

SAN FRANCISCO: Versaggi Biocommunications has added two new accounts to its medical/biotech roster and is nearing an agreement with a third, president Charles Versaggi told PRWeek last week.

Uros has hired Versaggi Biocomm to lay the groundwork for an anticipated market introduction in 2000, while Xenogen is hoping Versaggi can change its image from that of a niche provider of pharmaceuticals to an across-the-board medical provider.

Versaggi also hinted that his firm is close to re-establishing its relationship with London-based Oxford Molecular Group - a technology supplier for the pharmaceutical, chemical, biotechnology and academic markets - which wants a greater US presence.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.